PMID- 22023452
OWN - NLM
STAT- MEDLINE
DCOM- 20120413
LR  - 20231104
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Print)
IS  - 0902-4441 (Linking)
VI  - 88
IP  - 3
DP  - 2012 Mar
TI  - Deferasirox treatment of iron-overloaded chelation-naive and prechelated patients 
      with myelodysplastic syndromes in medical practice: results from the 
      observational studies eXtend and eXjange.
PG  - 260-8
LID - 10.1111/j.1600-0609.2011.01726.x [doi]
AB  - EXtend and eXjange were prospective, 1-yr, non-interventional, observational, 
      multicentre studies that investigated deferasirox, a once-daily oral iron 
      chelator, in iron-overloaded chelation-naive and prechelated patients with 
      myelodysplastic syndromes (MDS), respectively, treated in the daily-routine 
      setting of office-based physicians. No inclusion or exclusion criteria or 
      additional monitoring procedures were applied. Deferasirox was administered as 
      recommended in the European Summary of Product Characteristics. Haematological 
      parameters and adverse events (AEs) were collected at two-monthly intervals. Data 
      from 123 chelation-naive patients with MDS (mean age 70.4 yrs) with median 
      baseline serum ferritin level of 2679 (range 184-16,500) ng/mL, and 44 
      prechelated patients with MDS (mean age 69.6 yrs) with median baseline serum 
      ferritin level of 2442 (range 521-8565) ng/mL, were assessed. The mean prescribed 
      daily dose of deferasirox at the first visit was 15.7 and 18.7 mg/kg/d, 
      respectively. Treatment with deferasirox produced a significant reduction in 
      median serum ferritin levels in chelation-naive patients with MDS from 2679 to 
      2000 ng/mL (P = 0.0002) and a pronounced decrease in prechelated patients with 
      MDS from 2442 to 2077 ng/mL (P = 0.06). The most common drug-related AEs were 
      gastrointestinal, increased serum creatinine levels and rash. These studies 
      demonstrate that deferasirox used in physicians' medical practices is effective 
      in managing iron burden in transfusion-dependent patients with MDS.
CI  - (c) 2011 John Wiley & Sons A/S.
FAU - Gattermann, Norbert
AU  - Gattermann N
AD  - Department of Hematology, Oncology and Clinical Immunology, 
      Heinrich-Heine-University, Dusseldorf, Germany. gattermann@med.uni-duesseldorf.de
FAU - Jarisch, Andrea
AU  - Jarisch A
FAU - Schlag, Rudolf
AU  - Schlag R
FAU - Blumenstengel, Klaus
AU  - Blumenstengel K
FAU - Goebeler, Mariele
AU  - Goebeler M
FAU - Groschek, Matthias
AU  - Groschek M
FAU - Losem, Christoph
AU  - Losem C
FAU - Procaccianti, Maria
AU  - Procaccianti M
FAU - Junkes, Alexia
AU  - Junkes A
FAU - Leismann, Oliver
AU  - Leismann O
FAU - Germing, Ulrich
AU  - Germing U
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20111124
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Benzoates)
RN  - 0 (Iron Chelating Agents)
RN  - 0 (Triazoles)
RN  - 9007-73-2 (Ferritins)
RN  - V8G4MOF2V9 (Deferasirox)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Benzoates/administration & dosage/adverse effects/*therapeutic use
MH  - Deferasirox
MH  - Female
MH  - Ferritins/blood
MH  - Humans
MH  - Iron Chelating Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Iron Overload/*complications/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*complications/therapy
MH  - Prospective Studies
MH  - Transfusion Reaction
MH  - Triazoles/administration & dosage/adverse effects/*therapeutic use
PMC - PMC3505370
EDAT- 2011/10/26 06:00
MHDA- 2012/04/14 06:00
CRDT- 2011/10/26 06:00
PHST- 2011/10/26 06:00 [entrez]
PHST- 2011/10/26 06:00 [pubmed]
PHST- 2012/04/14 06:00 [medline]
AID - 10.1111/j.1600-0609.2011.01726.x [doi]
PST - ppublish
SO  - Eur J Haematol. 2012 Mar;88(3):260-8. doi: 10.1111/j.1600-0609.2011.01726.x. Epub 
      2011 Nov 24.